Jakafi and Sinus congestion - a phase IV clinical study of FDA data

Summary:

We study 52,363 people who have side effects when taking Jakafi. Sinus congestion is found, especially among people who are female, 60+ old, have been taking the drug for < 1 month, also take Amlodipine and have Polycythaemia vera.

The phase IV clinical study analyzes which people take Jakafi and have Sinus congestion. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Oct, 01, 2023

52,363 people reported to have side effects when taking Jakafi.
Among them, 66 people (0.13%) have Sinus congestion.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is used in primary myelofibrosis. Currently, eHealthMe is studying from 52,440 Jakafi users.

What is Sinus congestion?

Sinus congestion (blockage of sinus) is found to be associated with 1,831 drugs and 915 conditions by eHealthMe. Currently, we are studying 20,089 people who have Sinus congestion.

Number of Jakafi and Sinus congestion reports submitted per year:

Time on Jakafi when people have Sinus congestion *:

Gender of people who have Sinus congestion when taking Jakafi *:

female: 66.67 %
male: 33.33 %

Age of people who have Sinus congestion when taking Jakafi *:

Common drugs people take besides Jakafi *:

Common side effects people have besides Sinus congestion *:

Fatigue (feeling of tiredness): 38 people, 57.58%
Platelet Count Abnormal: 30 people, 45.45%
Cough: 30 people, 45.45%
High Blood Cholesterol: 26 people, 39.39%
Red Blood Cell Count Decreased: 26 people, 39.39%
Itching: 23 people, 34.85%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 22 people, 33.33%
Head Injury: 19 people, 28.79%
Weight Increased: 19 people, 28.79%
Nausea And Vomiting: 19 people, 28.79%

Common conditions people have *:

Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 37 people, 56.06%
High Blood Pressure: 5 people, 7.58%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 5 people, 7.58%
Diarrhea: 5 people, 7.58%
Erection Problems: 5 people, 7.58%
Abdominal Pain Lower: 5 people, 7.58%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 5 people, 7.58%
Vitamin B Complex Deficiency: 4 people, 6.06%
Essential Thrombocythaemia (chronic blood cancer): 4 people, 6.06%
Libido Disorder (a sexual dysfunction relating to loss of sexual desire): 3 people, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Jakafi and have Sinus congestion?

Check whether Sinus congestion is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Jakafi side effects by duration, gender and age:

Jakafi side effects (52,440 reports)

Sinus congestion treatments and more:

Sinus congestion (20,089 reports)

Common drugs associated with Sinus congestion:

All the drugs that are associated with Sinus congestion:

Sinus congestion (1,831 drugs)

Common conditions associated with Sinus congestion:

Rheumatoid arthritis: 2,365 reports
Asthma: 1,386 reports
Psoriasis: 832 reports
Primary pulmonary hypertension: 738 reports
High blood pressure: 679 reports
Crohn's disease: 611 reports
Multiple sclerosis: 488 reports

All the conditions that are associated with Sinus congestion:

Sinus congestion (915 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ruxolitinib phosphate (the active ingredients of Jakafi) and Jakafi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.